Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.

Published in: Applied health economics and health policy (2020)

Secukinumab appears to be cost effective compared with other DMARDs for the treatment of active PsA in biologic-naïve and biologic-experienced populations in Germany.

Keyphrases

rheumatoid arthritis
prostate cancer
ankylosing spondylitis
combination therapy
radical prostatectomy
replacement therapy
genetic diversity